Within half a century of the discovery of genetic material manipulation, RNA therapeutics is expected to take the center stage in the global pharmaceutical industry. Propelled by recent technological advancements, gene manipulation will be critical in developing personalized medicine and meeting the specific requirements of patients. The success of the COVID-19 mRNA vaccines has ignited big pharma's interest in the potential of RNA therapeutics. Today, the major industrial players are actively exploring new grounds, broadening the scope of RNA therapeutics and vaccines.
For example, the partnership between Pfizer and BioNTech was one of the most significant acquisitions in 2020 that showed big pharma's intention to use RNA research through collaborations. Researchers claim that this has impacted not just companies with products in the clinical stages but also certain academic laboratories. As a result, there will probably be more RNA-focused activities in the upcoming years. There is no doubt that RNA will be vital for raising the bar of drugs. Novel innovations are now actively hitting the market with an expectation to alter the course of drug manufacturing.
In this article, we have listed the top trends in the RNA therapeutic industry:Growing Application Of noncoding RNA Currently, several fields are working hard to investigate non-coding RNA's potential as a cancer therapy. Recent research state that the therapeutic target of ncRNA has demonstrated success. ncRNAs are increasingly recognized as a means of overcoming this challenge despite the complicated mechanisms underlying chemosensitivity and chemoresistance. Among the processes that ncRNAs support in conjunction with the recurrence and metastasis of malignant tumors are apoptosis, DNA damage repair, cell cycle checkpoints, autophagy, the epithelial-mesenchymal transition, and the production of cancer stem cells. Cancer radioresistance is significantly influenced by ncRNAs.
“One advantage with noncoding RNA is that it can be so tumor-specific,” says Sarah Diermeier, Rutherford Discovery fellow at the University of Otago, whose own work is focused on noncoding RNA in oncology from which a candidate could enter the clinic in the upcoming years. No doubt, ncRNA has a huge potential in gene regulation, however since its expression levels are lower, the industry will have to develop cutting-edge technology to harness its potential.
RNA and Golden Age of Vaccinology Due to its high potency, the ability for quick creation, the possibility for low-cost manufacturing and safe administration, and the potential for rapid development, mRNA vaccines provide a viable alternative to conventional vaccination techniques. But up until recently, the instability and ineffective in vivo distribution of mRNA limited their applicability. These problems have now mostly been resolved by recent technology advancements, and many mRNA vaccination platforms against infectious illnesses and various cancer types have shown positive outcomes in both animal models and people.
RNA-based vaccinations will likely play a significant role in the future of human health since they are the result of years of mRNA clinical work built atop a foundation anchored in basic research. In order to successfully provide a new era of vaccinations built on a better understanding of the immune system—down to the cellular and molecular levels—the scientific community will need to work together to drive efficiency and knowledge sharing. The market for RNA-based therapies is expected to grow to more than $25 billion by 2030, which is encouraging for RNA technology.
The way toward CRISPR Technologies With the development of RNAi, scientists were able to comprehend how each gene was affected when its expression was decreased. The presence of several RNAi medications on the market is promising. While there are benefits to its therapeutic application, such as the capacity to target and regulate the duration and intensity of gene silencing, there are also drawbacks, such as undesirable effects on other genes.
The foundation set by RNAi allowed the CRISPR-Cas9 system to succeed in permanent gene deletion as well as the insertion of novel gene functions, demonstrating the technology's enormous potential to create and alter gene function. With the possibility of single-dose therapies that permanently modify a patient's DNA and might possibly treat previously incurable diseases, the most recent developments in CRISPR techniques are significantly changing the quality of data in early target drug discovery. While there are many potential ways to employ CRISPR in genetic medicine, one method has previously been tested in clinical trials: delivering essential CRISPR reagents like RNAs.
Moving Ahead In the future, it's likely that a population of various RNA substrates would code and cascade multiple proteins to activate several pathways to kill cancer cells or treat autoimmune illnesses in place of a monotherapy. The main challenges of getting these compounds into cells have made significant progress recently, but thanks to advances in lipid chemistry, new products that improve this sector are expected to emerge. The next phase in this process may involve lowering toxicity and improving the targeting of the RNA to specified regions or even specific cell types.
, CDSCO.jpg)
